{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:07:10Z","timestamp":1792145230463,"version":"4.4.0"},"reference-count":110,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The introduction of tyrosine kinase inhibitors (TKIs) has transformed the treatment of chronic myeloid leukemia (CML). Each approved TKI has its own risk-benefit profile, and patients have choices across lines of therapy. Identifying the initial and subsequent treatment that will lead to the best possible outcome for individual patients is challenging. In this review, we summarize data for each approved TKI across lines of therapy in patients with CML in chronic phase, highlighting elements of each agent\u2019s safety and efficacy profile that may impact patient selection, and provide insights into individualized treatment sequencing decision-making aimed at optimizing patient outcomes.<\/jats:p>","DOI":"10.3389\/fonc.2024.1369246","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T01:02:49Z","timestamp":1719795769000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Exploring treatment decision-making in chronic myeloid leukemia in chronic phase"],"prefix":"10.3389","volume":"14","author":[{"given":"David","family":"Andorsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsi","family":"Kota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra","family":"Sweet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/GO.21.00194","article-title":"Magnitude and temporal trend of the chronic myeloid leukemia: on the basis of the Global Burden of Disease study 2019","volume":"7","author":"Hu","year":"2021","journal-title":"JCO Glob Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0007","article-title":"Chronic myeloid leukemia, version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01589-y","article-title":"Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial","volume":"36","author":"Br\u00fcmmendorf","year":"2022","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01306-1","article-title":"Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: Results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24536","article-title":"Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and\/or nilotinib","volume":"91","author":"Cortes","year":"2016","journal-title":"Am J Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.164","article-title":"Chronic myeloid leukemia: sequencing of TKI therapies","volume":"2016","author":"Cortes","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B12","article-title":"The \u201chit hard and hit early\u201d approach to the treatment of chronic myeloid leukemia: implications of the updated National Comprehensive Cancer Network Clinical Practice Guidelines for routine practice","volume":"11","author":"Akard","year":"2013","journal-title":"Clin Adv Hematol Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2018.11.005","article-title":"What happens to intolerant, relapsed or refractory chronic myeloid leukemia patients without access to clinical trials","volume":"41","author":"Bosi","year":"2019","journal-title":"Hematol Transfus Cell Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.03.006","article-title":"Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm","volume":"15","author":"Jabbour","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/PPO.0000000000000165","article-title":"The role of new tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"22","author":"Pophali","year":"2016","journal-title":"Cancer J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e7342","DOI":"10.7759\/cureus.7342","article-title":"Risk stratification of chronic myeloid leukemia according to different prognostic scores","volume":"12","author":"Aijaz","year":"2020","journal-title":"Cureus"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020006911","article-title":"How to manage CML patients with comorbidities","volume":"2020","author":"Cortes","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B18","doi-asserted-by":"publisher","first-page":"494","DOI":"10.18553\/jmcp.2020.26.12.1494","article-title":"Freedman AN, et\u00a0al. Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients","volume":"26","author":"Rivera","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.05.019","article-title":"Cost-effectiveness of first-line tyrosine kinase inhibitor therapy initiation strategies for chronic myeloid leukemia","volume":"23","author":"Nguyen","year":"2020","journal-title":"Value Health"},{"key":"B22","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1186\/s13059-014-0461-8","article-title":"Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia","volume":"15","author":"Eiring","year":"2014","journal-title":"Genome Biol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.139337","article-title":"Chronic myeloid leukemia: reminiscences and dreams","volume":"101","author":"Mughal","year":"2016","journal-title":"Haematologica"},{"key":"B24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/ajh.24943","article-title":"Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors","volume":"93","author":"Alhuraiji","year":"2018","journal-title":"Am J Hematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003570","article-title":"Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression","volume":"5","author":"Clark","year":"2021","journal-title":"Blood Adv"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \"good-risk\" chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.3390\/cancers13194820","article-title":"Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance","volume":"13","author":"Alves","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","article-title":"Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors","volume":"31","author":"Patel","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4660","article-title":"Association of generic imatinib availability and pricing with trends in tyrosine knase inhibitor use in patients with chronic myelogenous leukemia","volume":"6","author":"Lyman","year":"2020","journal-title":"JAMA Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-017-0484-9","article-title":"Use patterns of first-line inhibitors of tyrosine kinase and time to change to second-line therapy in chronic myeloid leukemia","volume":"39","author":"Machado-Alba","year":"2017","journal-title":"Int J Clin Pharm"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-123950","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-154344","article-title":"Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy","volume":"113","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.9953","article-title":"Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression","volume":"26","author":"Khorashad","year":"2008","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-018-2422-6","article-title":"Characteristics and outcome of chronic myeloid leukemia patients with E255K\/V BCR-ABL kinase domain mutations","volume":"107","author":"Naqvi","year":"2018","journal-title":"Int J Hematol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11369","article-title":"Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation","volume":"92","author":"Nicolini","year":"2007","journal-title":"Haematologica"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10822","article-title":"Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain","volume":"92","author":"Soverini","year":"2007","journal-title":"Haematologica"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-197186","article-title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors","volume":"114","author":"Soverini","year":"2009","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-149948","article-title":"Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"B47","article-title":"Bosutinib for chronic phase chronic myeloid leukemia after imatinib failure: \u22658-year update of a phase 1\/2 Study","author":"Cortes","year":"2020"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0915-9","article-title":"Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(22)00882-5","article-title":"Asciminib provides durable molecular responses in patients with chronic myeloid leukemia in chronic phase (CML-CP) with the T315I mutation: Updated efficacy and safety data from a phase I trial","author":"Hughes","year":"2022"},{"key":"B50","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24423","article-title":"Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034","volume":"91","author":"Shah","year":"2016","journal-title":"Am J Hematol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01829-9","article-title":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL","volume":"37","author":"Hochhaus","year":"2023","journal-title":"Leukemia"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012082","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","first-page":"106458","DOI":"10.1016\/j.leukres.2020.106458","article-title":"The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase","volume":"98","author":"Manley","year":"2020","journal-title":"Leuk Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"Rea","year":"2021","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J Med Chem"},{"key":"B58","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/cncr.32504","article-title":"Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"126","author":"Naqvi","year":"2020","journal-title":"Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.4137\/CMO.S6413","article-title":"Efficacy and tolerability after unusually low doses of dasatinib in chronic myeloid leukemia patients intolerant to standard-dose dasatinib therapy","volume":"4","author":"Serpa","year":"2010","journal-title":"Clin Med Insights Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2018.02.013","article-title":"Efficacy and safety of nilotinib 300\u202fmg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study","volume":"67","author":"Hiwase","year":"2018","journal-title":"Leuk Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S92125","article-title":"Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment","volume":"9","author":"Kek\u00e4le","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2021.12.5.7","article-title":"Management of adverse events associated with tyrosine kinase inhibitor use in adult patients with chronic myeloid leukemia in chronic phase: An advanced practice perspective","volume":"12","author":"Bauer","year":"2021","journal-title":"J Adv Pract Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1480719","article-title":"Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib","volume":"17","author":"Breccia","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"B64","article-title":"Prescribing information","year":"2024"},{"key":"B65","article-title":"Prescribing information","year":"2023"},{"key":"B66","article-title":"Corp. Gleevec (imatinib). Prescribing information","year":"2024"},{"key":"B67","article-title":"America. Iclusig (ponatinib). Prescribing information","year":"2024"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00603","article-title":"Tyrosine kinase inhibitors available for chronic myeloid leukemia: Efficacy and safety","volume":"9","author":"Garcia-Gutierrez","year":"2019","journal-title":"Front Oncol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/ajh.25306","article-title":"Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY","volume":"94","author":"Hehlmann","year":"2019","journal-title":"Am J Hematol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2018.1.161","article-title":"The argument for using imatinib in CML","volume":"2018","author":"Claudiani","year":"2018","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018025874","article-title":"Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv"},{"key":"B72","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/hon.2606","article-title":"Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart","volume":"37","author":"Caocci","year":"2019","journal-title":"Hematol Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220970616","article-title":"Predictors of tyrosine kinase inhibitor adherence trajectories in patients with newly diagnosed chronic myeloid leukemia","volume":"27","author":"Clark","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"B74","doi-asserted-by":"publisher","first-page":"11045","DOI":"10.3390\/ijerph182111045","article-title":"Assessment of oral chemotherapy nonadherence in chronic myeloid leukemia patients using brief measures in community cancer clinics: A pilot study","volume":"18","author":"Davis","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2021.158","article-title":"Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia","volume":"36","author":"Kim","year":"2021","journal-title":"Korean J Intern Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.06.007","article-title":"Identifying tyrosine kinase inhibitor nonadherence in chronic myeloid leukemia: Subanalysis of TAKE-IT pilot study","volume":"18","author":"Leader","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B77","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11096-020-01070-9","article-title":"Adherence to tyrosine kinase inhibitors among adult chronic myeloid leukemia patients in a Malaysia hospital","volume":"43","author":"Lee","year":"2021","journal-title":"Int J Clin Pharm"},{"key":"B78","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.clml.2016.02.040","article-title":"Comprehensive evaluation of adherence to therapy, its associations, and its implications in patients with chronic myeloid leukemia receiving imatinib","volume":"16","author":"Unnikrishnan","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1535113","article-title":"The potential health gain and cost savings of improving adherence in chronic myeloid leukemia","volume":"60","author":"Ector","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2012.30","article-title":"Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy","volume":"2","author":"Deangelo","year":"2012","journal-title":"Blood Cancer J"},{"key":"B81","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s12032-017-0958-6","article-title":"Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors","volume":"34","author":"Rychter","year":"2017","journal-title":"Med Oncol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"95","DOI":"10.4137\/CMO.S32822","article-title":"Is adherence to imatinib mesylate treatment among patients with chronic myeloid leukemia associated with better clinical outcomes in Qatar","volume":"10","author":"Al-Dewik","year":"2016","journal-title":"Clin Med Insights Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23408","article-title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors","volume":"88","author":"Cortes","year":"2013","journal-title":"Am J Hematol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-415307","article-title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181456","article-title":"Flumatinib for newly diagnosed chronic phase chronic myeloid leukemia: An open-label, multi-center study","volume":"142","author":"Wen","year":"2023","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","first-page":"6359","DOI":"10.1182\/blood-2023-174679","article-title":"Flumatinib versus imatinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase: A propensity score matching study from real-world data","volume":"142","author":"Xie","year":"2023","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1600","article-title":"Flumatinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: A phase III, randomized, open-label, multi-center FESTnd study","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0259076","article-title":"Enabling access to molecular monitoring for chronic myeloid leukemia patients is cost effective in China","volume":"16","author":"Maheshwari","year":"2021","journal-title":"PloS One"},{"key":"B89","unstructured":"The study of the efficacy and the safety of flumatinib vs imatinib as first line treatment in patients with CML"},{"key":"B90","unstructured":"Flumatinib efficacy and safety for new diagnosed chronic myeloid leukemia"},{"key":"B91","unstructured":"A study of the efficacy and safety of flumatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.42","article-title":"Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1","volume":"29","author":"Zabriskie","year":"2015","journal-title":"Leukemia"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0957","article-title":"Phase III clinical trial (RERISE study) results of efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia","volume":"23","author":"Kwak","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16381","article-title":"Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)","volume":"189","author":"Do","year":"2020","journal-title":"Br J Haematol"},{"key":"B95","unstructured":"A phase 3 study for the efficacy and safety of radotinib in CP-CML patients with failure or intolerance to previous TKIs"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01680-9","article-title":"Olverembatinib: first approval","volume":"82","author":"Dhillon","year":"2022","journal-title":"Drugs"},{"key":"B97","unstructured":"Olverembatinib included in newest guidelines on Chronic myeloid leukemia (CML) management from the National Comprehensive Cancer Network (NCCN)"},{"key":"B98","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-022-01334-z","article-title":"Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1\/2 trial","volume":"15","author":"Jiang","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B99","unstructured":"Treatment with olverembatinib in CML-CP patients who failed to at least two previously administered second-generation TKIs"},{"key":"B100","unstructured":"Jorge E. Cortes, MD, on CML: efficacy and safety of vodobatinib"},{"key":"B101","volume-title":"Jorge E. Cortes, MD, on CML: efficacy and safety of vodobatinib","author":"Cortes","year":"2022"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139847","article-title":"Phase 1 trial of vodobatinib, a novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI): Activity in CML chronic phase patients failing TKI therapies including ponatinib","volume":"136","author":"Cortes","year":"2022","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-152548","article-title":"An update of safety and efficacy results from phase 1 dose-escalation and expansion study of vodobatinib, a novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI), in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) failing prior TKI therapies","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162700","article-title":"Elvn-001, a next generation ATP-competitive ABL1 tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia","volume":"140","author":"Gross","year":"2022","journal-title":"Blood"},{"key":"B105","unstructured":"A phase 1a\/1b study of ELVN-001 for the treatment chronic myeloid leukemia (CML)"},{"key":"B106","unstructured":"CARDINAL - A clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TERN-701 in participants with chronic myeloid leukemia"},{"key":"B107","unstructured":"Our programs"},{"key":"B108","unstructured":"Terns pharmaceuticals announces orphan drug designation granted to TERN-701 for the treatment of chronic myeloid leukemia"},{"key":"B109","unstructured":"Announcement of unaudited interim results for the six months ended June 30, 2020"},{"key":"B110","unstructured":"Our pipeline"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1369246\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T01:02:59Z","timestamp":1719795779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1369246\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":110,"alternative-id":["10.3389\/fonc.2024.1369246"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1369246","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,1]]},"article-number":"1369246"}}